Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder

Overview

Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 2015

Detailed Description

Overactive bladder is a clinical syndrome characterized urgency, frequency and nocturia. Infection or other obvious causes must be excluded. The overactive bladder is loss of inhibition of the detrusor muscle during the filling or emptying of the bladder. Specific receptors and neurotransmitters have role in development of overactive bladder. These includes adrenergic, cholinergic, non-adrenergic, non-cholinergic receptors and interstitial cells. Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder. The investigators believe that our findings will shed light on treatment.

Arms, Groups and Cohorts

  • women with metabolic syndrome and overactive bladder
    • women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits: Abdominal obesity, defined as a waist circumference in men ≥88 cm Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose
  • women with overactive bladder
    • women with urinary urgency+frequency+nocturia
  • healthy control group
    • women not overactive bladder and metabolic syndrome

Clinical Trial Outcome Measures

Primary Measures

  • nerve growth factor levels
    • Time Frame: 3 months
    • association between nerve growth factor levels and overactive bladder

Secondary Measures

  • urge incontinence
    • Time Frame: 3 months
    • number of urge incontinence
  • overactive bladder symptoms
    • Time Frame: 3 months
    • number of nocturia,urgency,frequency

Participating in This Clinical Trial

Inclusion Criteria

  • women with urgency, nocturia and frequency – Abdominal obesity, defined as a waist circumference in men ≥88 cm – Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides – Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C – Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure – Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose Exclusion Criteria:

  • Chronic obstructive pulmonary disease allergy – Psychiatric disorders – Urinary tract infection – Neurological diseases – Metabolic diseases – Pure stress or mixed urinary incontinence – History of pelvic surgery – Diabetes mellitus

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Bakirkoy Dr. Sadi Konuk Research and Training Hospital
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.